Last reviewed · How we verify
CABLIVI (CAPLACIZUMAB-YHDP)
CABLIVI (generic name: CAPLACIZUMAB-YHDP) is a drug developed by ABLYNX NV. It is currently FDA-approved for Thrombotic thrombocytopenic purpura.
At a glance
| Generic name | CAPLACIZUMAB-YHDP |
|---|---|
| Sponsor | ABLYNX NV |
| Target | von Willebrand factor |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Thrombotic thrombocytopenic purpura
Common side effects
- Epistaxis
- Headache
- Gingival bleeding
- Fatigue
- Urticaria
- Pyrexia
- Paresthesia
- Dyspnea
- Back pain
- Injection site hemorrhage
- Catheter site hemorrhage
- Myalgia
Serious adverse events
- Epistaxis
- Subarachnoid hemorrhage
- Hemorrhage urinary tract
- Hemorrhage
Key clinical trials
- Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (N/A)
- An Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-media (Phase 3)
- Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)- REACT-2020 (N/A)
- Retrospective Data Collection of Pediatric Patients With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) Treated With Caplacizumab (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CABLIVI CI brief — competitive landscape report
- CABLIVI updates RSS · CI watch RSS
- ABLYNX NV portfolio CI
Frequently asked questions about CABLIVI
What is CABLIVI?
CABLIVI (CAPLACIZUMAB-YHDP) is a pharmaceutical drug developed by ABLYNX NV, indicated for Thrombotic thrombocytopenic purpura.
What is CABLIVI used for?
CABLIVI is indicated for Thrombotic thrombocytopenic purpura.
Who makes CABLIVI?
CABLIVI is developed and marketed by ABLYNX NV (see full ABLYNX NV pipeline at /company/ablynx-nv).
What is the generic name of CABLIVI?
CAPLACIZUMAB-YHDP is the generic (nonproprietary) name of CABLIVI.
What development phase is CABLIVI in?
CABLIVI is FDA-approved (marketed).
What are the side effects of CABLIVI?
Common side effects of CABLIVI include Epistaxis, Headache, Gingival bleeding, Fatigue, Urticaria, Pyrexia. Serious adverse events: Epistaxis, Subarachnoid hemorrhage, Hemorrhage urinary tract, Hemorrhage.
What does CABLIVI target?
CABLIVI targets von Willebrand factor.
Related
- Target: All drugs targeting von Willebrand factor
- Manufacturer: ABLYNX NV — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Thrombotic thrombocytopenic purpura
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing